Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma

Table 5 Comparison between the postoperative complete remission (-) tyrosine kinase inhibitors (+) and postoperative complete remission (-)tyrosine kinase inhibitors (-) groups

	Category	POCR (-)/TKI (+)	POCR (-)/TKI (-)	P value
Age	< 60/≥ 60	4/2	7/9	0.6351
Sex	Male/female	6/0	15/1	1.0000
HBV and/or HCV	-/ +	2/4	4/12	1.0000
Alb (g/dL)	< 3.7/≥ 3.7	1/5	9/7	0.1619
T-Bil (mg/dL)	≤ 0.8/> 0.8	4/2	9/7	1.0000
PT (%)	< 90/≥ 90	2/4	7/9	1.0000
ICGR15 (%)	< 15/≥ 15	4/2	10/6	1.0000
AFP (ng/mL)	< 200/> 200	4/2	8/8	0.6462
PIVKA-II	< 100/≥ 100	0/6	1/15	1.0000
Child-pugh class	A/B	6/0	13/3	0.5325
Tumor size (cm)	< 10/≥ 10	4/2	6/10	0.3476
Differentiation	Wel or mod/por	4/2	8/8	0.6462
pN	-/ +	5/1	16/0	0.2727
Macrovascular invasion	-/ +	0/6	5/11	0.2663
Distant metastasis	-/ +	5/1	14/2	1.0000
BCLC stage	B/C	2/4	7/9	1.0000
Anatomical hepatectomy	-/ +	0/6	1/15	1.0000
Number of tumors in the remnant liver	1-3/≥ 4	0/6	5/11	0.2663

POCR: Postoperative complete remission; TKIs: Tyrosine kinase inhibitors; PT: Prothrombin time; ICGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence/antagonist-II; BCLC: Barcelona Clinic Liver Cancer.